Efficiency of Levetiracetam Intravenous in Association With Clonazepam Versus Clonazepam Alone in Prehospital Care of Generalised Tonicoclonic Status Epilepticus
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 203
- Locations
- 1
- Primary Endpoint
- Patient's percentage having stopped convulsing in the 15 minutes following the injection. The stop of the crisis is defined as the stop of all epileptic movements (myoclonic, clonic or tonic)
Study Overview
Brief Summary
Compare the efficiency of the association, first line, the intravenous levetiracetam and the intravenous clonazepam, in that of a monotherapy of clonazepam intravenous in the pre-hospital treatment of tonicoclonic generalised status epilepticus.
Detailed Description
At this time, the prehospital treatment of the status epilepticus use some molecule ("FOSPHENYLOINE") with large contra-indications. In this case the physician is not able to know the past medical history of the patient, the biological examinations and so he can not decide which molecules he can use.
The levetiracetam is a knowledge medication in the epilepsy since more than twenty years. One of specificity of the levetiracetam is to be able to be used in all situations (no clinical or biological contre-indication). This molecule seems like to be very interesting to be used in prehospital system.
The goal of this study is to evaluate the association levetiracetam / clonazepam in first line in the prehospital treatment of the status epilepticus
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years
- •Patient taken care by a prehospital medical team participating in the study
- •Diagnosis of tonicoclonic generalized status epilepticus confirmed on the spot by a physician of the team.
Exclusion Criteria
- •Parent or the reliable person indicated by the patient present not giving its agreement for the inclusion
- •Pregnancy clinically detectable or known for close relations at the time of the status epilepticus
- •tonicoclonic generalized status epilepticus after anoxia post cardiac arrest
- •Patient having already received another treatment for the same episode of status epilepticus
- •Patient having already participated in the study during a previous episode of status epilepticus
- •Patient in "latent" status epilepticus. Definition : patient in the coma having epileptic demonstrations (CLONISMS MYOCLONISMS) small or invalid, contrasting with permanent generalized electric seizures on the EEG
- •Patient presenting certain diagnosis of pseudo name psychogenic seizure
- •Patient whose neurological status requires an immediate surgery (traumatism)
- •Patient having a hyper-responsiveness about the levetiracetam or about the other by-products of pyrrolidone or an one of the excipients
- •Patient having a hyper-responsiveness about the clonazepam, about the benzodiazepins or about one of the other constituents of the product
- •Patient under medical guardianship
- •Not membership in a schema of medical assurance.
Arms & Interventions
Clonazepam + placebo
Clonazepam IV 1 mg + placebo levetiracetam IV
Intervention: Clonazepam/Placebo levetiracetam IV (Drug)
Clonazepam + levetiracetam
Clonazepam IV 1 mg+ levetiracetam IV 2500 mg
Intervention: Levetiracetam/Clonazepam (Drug)
Outcomes
Primary Outcomes
Patient's percentage having stopped convulsing in the 15 minutes following the injection. The stop of the crisis is defined as the stop of all epileptic movements (myoclonic, clonic or tonic)
Time Frame: 15 minutes
Secondary Outcomes
- Frequency of adverse events and their severity(up to 15 days)
- Time of hospitalization(up to 15 days)
- Patient's percentage presenting signs of awakening to T35 min(35 minutes)
- Patient's percentage having been intubated for the general anesthesia(35 minutes)
- Patient's percentage having had a recurrence of epileptic seizure during the hospital follow-up(up to 15 days)
- Period between the first injection and the clinical stop of the convulsion(up to 15 minutes)
- Patient's percentage having received an injection of second anticonvulsivant to T15 min(15 minutes)
- Patient's percentage presenting convulsions or signs of awakening to the arrival to the hospital(up to 15 days)
- Period between the first injection and the presence of signs of awakening(up to three days)
- Patient's percentage having received the second injection of clonazepam to T5 min(5 minutes)
- Score of glasgow coma scale for the patients with no signs of awakening to T35 and to the arrival of the hospital(up to 35 minutes)
- Frequency of respiratory, hemodynamic and cardiac occurence of complications(up to 15 days)
- Analysis of the main criteria of efficiency by sous groups according to the etiology of the generalised tonic-clonic status epilepticus and according to this duration during the therapeutic clinical care(up to 15 days)